Products are selected by our editors, we may earn commission from links on this page.
A team at Jiangnan University in China reported in Nature Microbiology that raising levels of a single gut bacterium in diabetic mice pushed the animals to release more glucagon-like peptide-1, the hormone semaglutide imitates. The microbe is Bacteroides vulgatus, a common resident of the human large intestine. Mice that received a compound the bacterium makes during digestion produced more GLP-1 and more fibroblast growth factor 21, a hormone tied to sweet preference. Those mice controlled blood sugar better and reached for sugary food less often. The work was done in animals, not people.
This article was created with the assistance of AI and reviewed by our editorial team for accuracy and clarity.
The drug does not add anything new to the body
Semaglutide is often described as if it introduces a foreign chemical. It does not. GLP-1 is made in the gut lining of every healthy person, released after eating, and it does two jobs: it prompts insulin release when blood sugar rises, and it signals fullness to the brain. Semaglutide is a manufactured copy built to survive in the bloodstream far longer than the natural version, which breaks down within minutes. That is the real difference between the hormone and the injection. The Jiangnan team’s question followed from this: if the body already makes the signal, what makes it release more?
Ffar4 is the gut protein the chain starts with
The chain the researchers traced begins with a gut protein called Ffar4, which sits on intestinal cells and detects fatty acids from food. Mice bred without Ffar4 carried lower amounts of Bacteroides vulgatus in their intestines. With less of that bacterium present, the mice produced less FGF21, a hormone made largely in the liver that influences how strongly an animal seeks out sweet tastes. Lower FGF21 tracked with stronger sugar seeking. The sequence runs from a sensor protein to a bacterial population to a hormone to behavior, which is why no single link explains the result on its own.
Eighty-four blood samples anchored the human side
Nearly all of the experimental work ran in mice, but the researchers also examined blood from people: 60 individuals with type 2 diabetes and 24 people without it, 84 samples in total. In that group, mutations in the Ffar4 gene that impair FGF21 production were associated with a stronger preference for sugary food. That is a small sample by clinical trial standards, where diabetes drug trials routinely enroll thousands. It is enough to show the pattern is worth pursuing in humans and not enough to show it holds across populations. The authors describe the human data as supporting, not confirming.
Bacteroides vulgatus is already in most human guts
The bacterium at the center of this work is not exotic. Bacteroides vulgatus is one of the more common species in the human large intestine and is found in most adults, though in widely varying amounts. It breaks down complex carbohydrates that human enzymes cannot handle, and the compounds it releases in the process are what the study points to as the active signal. The researchers did not transplant a rare organism into the mice. They increased the abundance of one the animals already had, which is why the finding reads as a lever on existing biology rather than an introduction of something new.
Sugar craving was measured as a behavior, not a feeling
Mice cannot report a craving, so the researchers measured preference instead, tracking how strongly animals chose sweet solutions over plain water. That choice is the behavioral stand-in for what a person would describe as a sweet tooth. The mice given the bacterial compound showed both higher GLP-1 and higher FGF21, and their preference for the sweet option dropped. Separately, earlier work has shown that GLP-1 drugs raise FGF21 in mice, meaning the hormone pair moves together under more than one trigger. In humans, genetic variants that boost FGF21 have been linked to a stronger taste for sweet things.
Reading this as a yogurt recommendation misreads it
The most common error with microbiome research is treating a named species as a shopping instruction. Bacteroides vulgatus is not sold as a supplement, the study did not test any food or probiotic product, and the compound the bacterium produced during digestion was delivered to mice directly. Nothing in the work establishes that eating a particular item raises that species in a human gut, or that doing so would change blood sugar. Gut bacterial populations respond to long-term diet patterns in ways that remain poorly mapped. The finding identifies a mechanism to investigate, which is a different thing from a product to buy.
The cost gap explains why the research matters
Ozempic, made by Novo Nordisk and taken as a weekly self-administered injection, has often run above US$1,000 per month for people paying out of pocket, because most insurance plans cover it only for type 2 diabetes. That price sits behind the interest in any approach that works through the body’s own hormone production. The same price has also driven a counterfeit market: in 2024, a United Kingdom task force targeted illegal trade in so-called skinny jabs, running raids and monitoring online sellers and social platforms. A mechanism that needs no weekly injection would change that arithmetic entirely, if it survives human testing.
What the authors themselves said the work shows
The Jiangnan University researchers framed their result as a route toward preventing diabetes rather than treating it, and they stated plainly that more work is needed before the findings can be applied to human patients. Their broader argument is that food cravings are shaped by signals coming up from the gut, and that until recently the specific combination of genes, bacteria and bacterial products driving sugar craving was not mapped. That framing matters for how the result should be read. It is a description of a pathway, offered by the people who traced it, with the limits of a mouse study attached.
Two hormones moved together, which was the real finding
The headline result is not that one bacterium lowered blood sugar. It is that a single bacterial compound raised GLP-1 and FGF21 at the same time, hitting glucose regulation and sweet preference through one input. Semaglutide works on the GLP-1 side. The mouse data suggest the gut can reach both. That is why the authors treat the pathway as worth pursuing, and why nothing here changes what a person with type 2 diabetes should do. Anyone taking or considering a GLP-1 medication should talk to the clinician managing their care rather than acting on an animal study.